Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma

NCT05862012 is registered in ClinicalTrials.gov with Ichnos Sciences SA as lead sponsor.

NCT NCT05862012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05862012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Ichnos Sciences SA
Phase
Phase 1
Overall status
Recruiting
Start date
November 1, 2023
Completion date
July 31, 2027
Enrollment
200 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma